Drug Safety

, Volume 12, Issue 1, pp 26–31 | Cite as

A Comparative Review of the Adverse Effect Profiles of Heparins and Heparinoids

  • Lars C. Borris
  • Micheal R. Lassen
Review Articles Drug Experience

Summary

On the basis of the results of the 11 studies reviewed, thromboprophylaxis with unfractionated heparin, low molecular weight (LMW) heparin or a heparinoid (danaparoid sodium; Org 10172) in patients undergoing total hip replacement did not show any important clinical differences with respect to the tolerability profiles of the different compounds. However, as a result of the great variability in the presentation and evaluation of blood losses and bleeding complications in these studies, it is mandatory to perform a direct comparison of the different compounds in question in a double-blind, prospective clinical study.

Keywords

Heparin Unfractionated Heparin Dalteparin Nadroparin Dihydroergotamine 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    European Consensus Statement. Prevention of venous thromboembolism. Int Angiol 1992; 11: 151–9Google Scholar
  2. 2.
    Lassen MR, Borris LC, Christiansen HM, et al. Clinical trials with low molecular weight heparins in the prevention of postoperative thromboembolic complications: a meta-analysis. Semin Thromb Hemost 1991; 17 Suppl. 3: 284–90PubMedGoogle Scholar
  3. 3.
    Leizorovicz A, Haugh MC, Chaupuis F-R, et al. Low molecular weight heparin in prevention of perioperative thrombosis. BMJ 1992; 305: 913–20PubMedCrossRefGoogle Scholar
  4. 4.
    Nurmohamed MT, Rosendaal FR, Butler HR, et al. Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis. Lancet 1992; 340: 152–6PubMedCrossRefGoogle Scholar
  5. 5.
    Meuleman DC. Orgaran (Org 10172): its pharmacological profile in experimental models. Haemostasis 1992; 22: 58–65PubMedGoogle Scholar
  6. 6.
    Mikhailidis DP, Fonesca VA, Barradas J, et al. Platelet activation following intravenous injection of a conventional heparin: absence of effect with a low molecular weight heparinoid (Org 10172). Br J Pharmacol 1987; 24: 415–24CrossRefGoogle Scholar
  7. 7.
    Meuleman DC, van Dinther T, Hobbelen PMJ, et al. Effects of the low molecular weight heparinoid Org 10172 in experimental thrombosis and bleeding models: comparison with heparin. Thromb Haemorrh Disord 1990; 2: 25–9Google Scholar
  8. 8.
    Dechavanne M, Ville D, Berruyer M, et al. Randomized trial of a low-molecular-weight heparin (Kabi 2165) versus adjusted-dose subcutaneous standard heparin in the prophylaxis of deep-vein thrombosis after elective hip surgery. Haemostasis 1989; 1: 5–12Google Scholar
  9. 9.
    Reilmann H, Bosch U, Creutzig H, et al. Thrombosis prophylaxis with low molecular weight heparin plus dihydro-ergotamine in operations on the lower extremity. Perfusion 1989; 234: 230–4Google Scholar
  10. 10.
    Mätzsch T, Bergqvist D, Fredin H, et al. Low molecular weight heparin compared with dextran as prophylaxis against thrombosis after total hip replacement. Acta Chir Scand 1990; 156: 445–50PubMedGoogle Scholar
  11. 11.
    Lassen MR, Borris LC, Christiansen HM, et al. Prevention of thromboembolism in 190 hip arthroplasties: comparison of LMW heparin and placebo. Acta Orthop Scand 1991; 62: 33–8PubMedCrossRefGoogle Scholar
  12. 12.
    Tørholm C, Broeng L, Jørgensen PS, et al. Thromboprophylaxis by low-molecular-weight heparin in elective hip surgery. J Bone Joint Surg Br 1991; 73: 434–8PubMedGoogle Scholar
  13. 13.
    The Danish Enoxaparin Study Group. Low-molecular-weight heparin (Enoxaparin) vs Dextran 70: the prevention of postoperative deep vein thrombosis after total hip replacement. Arch Intern Med 1991; 151: 1621–4CrossRefGoogle Scholar
  14. 14.
    Eriksson BI, Kälebo P, Anthmyr A, et al. Prevention of deep vein thrombosis and pulmonary embolism after total hip replacement: comparison of a low molecular weight heparin and unfractionated heparin. J Bone Joint Surg Am 1991; 73: 484–93PubMedGoogle Scholar
  15. 15.
    Leyvraz PF, Bachmann F, Hoek J, et al. Prevention of deep vein thrombosis after hip replacement: randomised comparison between unfractionated heparin and low molecular weight heparin. BMJ 1991; 303: 543–8PubMedCrossRefGoogle Scholar
  16. 16.
    The German Hip Arthroplasty Trial (GHAT) Group. Prevention of deep vein thrombosis with low molecular-weight heparin in patients undergoing total hip replacement: a randomized trial. Arch Orthop Trauma Surg 1992; 111: 110–20CrossRefGoogle Scholar
  17. 17.
    Leyvraz P, Bachmann F, Bohnet J, et al. Thromboembolic prophylaxis in total hip replacement: a comparison between the low molecular weight heparinoid Lomoparan and heparin-dihydroergotamine. Br J Surg 1992; 79: 911–4PubMedCrossRefGoogle Scholar
  18. 18.
    Hoek JA, Nurmohamed MT, Hamelynck KJ, et al. Prevention of deep vein thrombosis following total hip replacement by low molecular weight heparinoid. Thromb Haemost 1992; 67: 28–32PubMedGoogle Scholar
  19. 19.
    Ritter MA, Hamilton CW. Analysis of warfarin and low-dose heparin as thromboembolism prophylaxis in total hip replacement patients. Ann Surg 1975; 101: 896–901CrossRefGoogle Scholar
  20. 20.
    Flordal PA, Neander G. Blood loss in total hip replacement. A retrospective study. Arch Orthop Trauma Surg 1991; 111: 34–8CrossRefGoogle Scholar
  21. 21.
    Harkess JW. Arthroplasty of hip. In: Crenshaw AH, editor. Campbell’s operative orthopaedics. St Louis: Mosby Year Book, 1992: 441–626Google Scholar
  22. 22.
    Strange-Vognsen HH, Tørholm C, Lebech A, et al. Hematomas and subcutaneous suture techniques in total hip replacement. An ultrasound study. Arch Orthop Trauma Surg 1991; 111: 51–2PubMedCrossRefGoogle Scholar
  23. 23.
    Sharrock NE, Brien WW, Salvati EA, et al. The effect of intravenous fixed-dose heparin during total hip arthroplasty on the incidence of deep-vein thrombosis. J Bone Joint Surg Am 1990; 72: 1456–61PubMedGoogle Scholar
  24. 24.
    Bergqvist D, Gudmundsson G, Hallböök T. Does thromboprophylaxis increase the risk for infectious complications after total hip replacement? Vasa 1985; 14: 269–71PubMedGoogle Scholar
  25. 25.
    Chong BH, Ismail F, Chesterman CN, et al. Heparin-induced thrombocytopenia: mechanism of interaction of the heparin-dependent antibody with platelets. Br J Haematol 1989; 73: 235–40PubMedCrossRefGoogle Scholar
  26. 26.
    Chong BH, Magnani HN. Orgaran in heparin-induced thrombocytopenia. Haemostasis 1992; 22: 85–91PubMedGoogle Scholar
  27. 27.
    Sonnenblick M, Oven A, Jacobsohn W. Hyper-transaminasemia with heparin therapy. BMJ 1975; 3: 77–9PubMedCrossRefGoogle Scholar
  28. 28.
    Christiansen HM, Lassen MR, Borris LC, et al. Biological tolerance of Logiparin, a low molecular weight heparin, used in patients undergoing total hip replacement. Semin Thromb Hemost 1991; 17 Suppl. 2: 224–7PubMedGoogle Scholar

Copyright information

© Adis International Limited 1995

Authors and Affiliations

  • Lars C. Borris
    • 1
  • Micheal R. Lassen
    • 1
  1. 1.The Venous Thrombosis Group, Department of OrthopaedicsAalborg HospitalAalborgDenmark

Personalised recommendations